Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Hellenic Cooperative Oncology Group150 enrolled

Overview

Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.

A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Ovarian Cancer

Interventions

PARP inhibitorDRUG

use at any line of treatment in patients with advanced ovarian cancer

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- women \>18 years old with advanced high grade ovarian cancer Exclusion Criteria: \-

Locations (1)

Adamantia Nikolaidi

Athens, Attica, Greece

Outcomes

Primary Outcomes

Evaluation of Progression Free Survival

Time frame: 12/2022

Secondary Outcomes

Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer

Time frame: 12/2021

Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer

Time frame: 12/2021

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.